Newer drugs for Visceral Leishmaniasis: A review

1Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Visceral Leishmaniasis (VL) is one of the most neglected tropical diseases worldwide. The diagnosis and treatment of this disease is quite complex. Sodium Antimony Gluconate (SAG) which used to be a very effective treatment has now developed resistance and is potentially a cardio-toxic drug. Pentamidine has now been discarded because of adverse effect of diabetes mellitus. Amphotericin-B is an effective drug but can cause nephrotoxicity. Miltefosine is a new oral effective drug which has recently been introduced in the kala-azar elimination program in the Indian subcontinent. Paromomycin is an injectable aminoglycoside which is quite cheap but can cause ototoxicity and nephrotoxicity. Sitamaquine, an oral antimalarial drug is still in phase-II trial stage. Combination Therapy is been tried with good results. Single dose Ambisome (liposomal Amphotericin-B) though costly is a very good alternative. © 2014 Science Publication.

Cite

CITATION STYLE

APA

Pandey, K., Singh, D., Bimal, S., Rabidas, V., Murti, K., Lal, C., & Das, P. (2014). Newer drugs for Visceral Leishmaniasis: A review. American Journal of Infectious Diseases. Science Publications. https://doi.org/10.3844/ajidsp.2014.68.70

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free